Acro Biomedical Co., Ltd. (ACBM)

Price$0.0260Cached quoteAs of 2026-09-05 15:19 UTC

AI: Overvalued

Active SEC filer, but effectively inactive trading marketACBM is still an SEC-reporting issuer, but its common stock remains on OTC Pink Limited with no active market makers or reliable published proprietary quotations.

The June 30, 2026 Form 10-Q states that the company had filed all required Exchange Act reports during the preceding 12 months and identifies it as a shell company. The same filing says ACBM is an unsolicited-only Pink Limited security, is not eligible for proprietary broker-dealer quotations, has no market makers and has no published quotes. Thus the issuer is not presently SEC-delinquent based on its latest filing, but trading liquidity is severely impaired and the market is effectively inactive.

No operating revenue and continuing lossesThe company reported no revenue for the first six months of 2026 and has generated no revenue since December 31, 2022.

For the six months ended June 30, 2026, ACBM reported zero revenue, operating expenses of $77,825 and a net loss of $65,130, versus a $25,863 loss in the comparable 2025 period. Management said its prior research and development work produced no marketable product and operations have been limited. With no current revenue base, conventional P/E and price-to-sales valuation measures are not meaningful.

Severe balance-sheet and funding riskAt June 30, 2026, the company had only $3,648 of assets against $448,437 of liabilities and a $444,789 stockholders' deficit.

Current liabilities included $385,387 due to related parties. Operating cash use was $60,325 during the first half of 2026 and was almost entirely financed by $59,875 of advances from a minority stockholder. Management and the auditor have identified substantial doubt about the company's ability to continue as a going concern. Management also reported ineffective disclosure controls and material weaknesses including lack of segregation of duties and insufficient qualified accounting personnel.

Last observable valuation is difficult to justify fundamentallyA third-party market-data page recorded a last trade of $0.026 on June 16, 2026 and a reported market capitalization of about $1.56 million, but that price is stale and not a reliable current quote.

The reported $1.56 million market capitalization contrasts with $3,648 of total assets, negative $444,789 book equity, zero first-half 2026 revenue and continuing losses. Because the issuer itself says there are no published proprietary quotes and all displayed interest is unsolicited, no dependable current market value can be established. Using the last observable valuation only as context, the positive equity valuation appears high relative to the reported operating and balance-sheet fundamentals, supporting an Overvalued classification with low price-confidence.

AI: News

CEO, chairman and director transition on September 2Yu-Ting Su resigned as director, chairman and chief executive officer, while the board appointed Shao-Hsiang Shih chairman/director and Jing-Zhou Chen CEO and CFO.

The September 2, 2026 Form 8-K says Su's resignation was not due to a disagreement with the company. Shih became director and chairman effective September 2, and Jing-Zhou Chen became chief executive officer and chief financial officer. The leadership transition is material given ACBM's very limited operating organization and previously disclosed concentration of management and financial-control duties.

August 13 quarterly filing confirmed continued financial distressThe Q2 2026 Form 10-Q reported zero revenue, a $65,130 six-month net loss, $3,648 of cash and a $444,789 working-capital deficit.

The filing also disclosed $385,387 due to related parties, $59,875 of first-half funding from a minority stockholder, substantial going-concern doubt and ineffective disclosure controls. A $20,000 customer payment was forfeited to the company as compensation for non-performance after the related order was terminated. Management continued to describe the company as having limited operations and no revenue since the end of 2022.

Loading local price history

Revenue

2017

2018

2019

2020

2021

2022

2023

2024

2025

Net income

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019 · Dec 31	2019 · Sep 30	2018	2017	2016	2015
Revenue	$0	$0	$0	$658,500	$1.2M	$687,964	$193,536	$1.4M	$8.0M	$510,000	—	—
Gross profit	—	—	$0	$140,500	$259,500	$159,404	$12,096	$135,400	$833,400	$51,000	—	—
Gross margin	—	—	—	21.34%	21.67%	23.17%	6.25%	10.00%	10.40%	10.00%	—	—
Research & development	—	$0	$4.8M	$10.1M	$5.3M	—	—	—	—	—	—	—
Operating expenses	$154,024	$37,958	$8.8M	$16.0M	$8.0M	$289,867	$434,847	$576,953	$317,850	$53,248	$43,428	$47,490
Operating income	−$154,024	−$37,958	−$8.8M	−$15.9M	−$7.7M	−$130,463	−$422,751	−$441,553	$515,550	−$2,248	$43,428	—
Operating margin	—	—	—	−2,409.98%	−642.47%	−18.96%	−218.44%	−32.61%	6.43%	−0.44%	—	—
EBITDA	−$91,992	−$37,958	−$8.8M	−$15.9M	—	—	—	—	—	—	—	—
EBITDA margin	—	—	—	−2,409.98%	—	—	—	—	—	—	—	—
Net income	−$101,146	−$42,297	−$8.8M	−$15.9M	−$7.7M	−$117,453	−$371,604	−$370,747	$419,660	−$2,248	−$43,428	−$47,490
Net profit margin	—	—	—	−2,410.24%	−642.82%	−17.07%	−192.01%	−27.38%	5.24%	−0.44%	—	—
Basic EPSper basic share	$0.00	$0.00	-$0.15	-$0.26	-$0.14	$0.00	-$0.01	-$0.01	$0.01	$0.00	$0.00	$0.00
Diluted EPSper diluted share	$0.00	$0.00	-$0.15	-$0.26	—	$0.00	-$0.01	-$0.01	$0.01	$0.00	$0.00	$0.00